Products

DeepRhythmAI
Medicalgorithmics
Cardiology AI
DeepRhythmAI is an FDA-cleared, cloud-based AI algorithm by Medicalgorithmics S.A. that revolutionizes cardiac arrhythmia detection and classification from ECG data, offering superior accuracy and efficiency for physicians.

See all 1 product →

About Medicalgorithmics

Medicalgorithmics S.A. is a Warsaw-listed medical technology company specializing in AI-powered, non-invasive solutions for cardiac arrhythmia diagnostics. The company leverages its extensive ECG database, containing over 3.0 billion annotated heartbeats, and a predictive analytics platform to enable more precise diagnoses and personalized treatment plans than traditional methods. Their flagship product, PocketECG, is an FDA-certified device that monitors and diagnoses approximately 430,000 patients annually across more than 25 countries.

Beyond PocketECG, Medicalgorithmics offers a suite of advanced diagnostic tools including Kardiobeat.ai, a wearable ECG monitor, and DeepRhythmAI (DRAI), FDA-cleared AI algorithms for arrhythmia detection and classification that can be integrated into third-party software and devices. They also provide the DeepRhythm Platform (DRP), an AI-powered cloud ECG platform for comprehensive arrhythmia analysis. Additionally, Medicalgorithmics is at the forefront of developing innovative solutions like the Virtual Cardiac Stress Test (VCAST), an AI-based system for non-invasive analysis of cardiac imaging data to assess coronary artery disease. The company is actively involved in research and development, collaborating with leading medical institutions worldwide to continuously improve its products and contribute to scientific publications and clinical trials.

What Physicians Need to Know

Specialization
Medicalgorithmics specializes in AI-powered and non-invasive solutions for cardiac diagnostics, focusing on improving health through intelligent technologies. They offer advanced solutions for cardiac arrhythmia diagnostics.
Key Products
Their flagship products include DeepRhythmAI (DRAI), DeepRhythm Platform (DRP), PocketECG, Kardiobeat.ai, and Virtual Cardiac Stress Test (VCAST).
Technology Stack
Medicalgorithmics leverages cutting-edge AI technology, including deep learning-based algorithms, Convolutional Neural Networks (CNNs), and Transformer models, to detect, classify, analyze, and report ECG data. Their solutions are cloud-based and hardware-agnostic.
Key Differentiators
Their solutions offer high diagnostic precision, automated processes, remote monitoring, scalability, and data security. DRAI, for instance, provides results with unprecedented accuracy and speed, significantly outperforming traditional analysis methods. They also boast an extensive ECG database with over 3.0 billion annotated heartbeats.
Certifications
Their AI-powered technology for cardiac arrhythmia diagnostics is FDA certified. DRP also holds an EU certificate (Regulation (EU) 2017/745 on Medical Devices), Medical Device License issued by Health Canada, and CE 0197.
Physician Tip

For physicians, Medicalgorithmics' solutions offer comprehensive heart rhythm analysis, providing detailed insights into every heartbeat, full arrhythmia detection (including onset and offset), and arrhythmia burden calculation. The near real-time intervention capabilities and accurate PVC and PAC counts enable prompt and effective heart condition management. The intuitive and user-friendly interfaces, combined with automated processes, aim to streamline clinical workflows and accelerate diagnosis time, allowing for more informed decisions and enhanced patient outcomes. The ability to switch between Holter, extended Holter, event, and telemetry modes without device changes or office visits enhances patient convenience and monitoring flexibility.

Medicalgorithmics' DeepRhythm Platform (DRP) and DeepRhythmAI (DRAI) are designed for seamless integration with various wearable ECG monitoring devices and third-party software and medical devices. They have established partnerships with companies like Wellysis (a Samsung spin-off) and Accyourate, integrating their AI algorithms and software with their respective devices and solutions. They are also actively pursuing collaborations with leading cardiac monitoring technology solution providers in the U.S. and global MedTech companies. This hardware-agnostic and interoperable approach allows healthcare providers to incorporate Medicalgorithmics' cutting-edge arrhythmia detection into their existing platforms, supporting telemedicine and at-home patient monitoring.

Products by Medicalgorithmics

1 product in the directory

DeepRhythmAI
Medicalgorithmics
Cardiology AI
DeepRhythmAI is an FDA-cleared, cloud-based AI algorithm by Medicalgorithmics S.A. that revolutionizes cardiac arrhythmia detection and classification from ECG data, offering superior accuracy and efficiency for physicians.

What the Web Says

Medicalgorithmics is a Polish company focused on AI-driven cardiology technology, with its flagship product being PocketECG. While the company is actively involved in technological partnerships and has reported strong revenue growth, comprehensive reviews from employees and product users are scarce on popular review platforms.

Overall: Mixed

Strengths

  • Advanced algorithmic system for ECG monitoring (PocketECG)
  • Combines software, hardware, and telecommunications into one platform
  • Physicians can access full-disclosure ECG data and statistical reports online
  • Built-in accelerometer to correlate physical activity to arrhythmia and symptoms
  • Strong revenue growth reported in recent quarters
  • Focus on expanding service portfolio in fast-growing market segments

Limitations

  • Limited employee reviews available, with some negative feedback regarding management style and recruitment practices
  • No product reviews found on G2, Capterra, or other major review sites
  • Some AI interpretations of ECGs (general AI, not specific to Medicalgorithmics) have been found to be inaccurate or misleading
  • Discontinuation of development on PocketECG 12Ch device to optimize resources

Based on reviews from: Comparably, G2, DAIC, GoWork.pl, Investing.com, Medicalgorithmics News, Reddit

Last updated: 2026-10-22

Videos

News, demos, and interviews about Medicalgorithmics.

Loading videos...

Videos load interactively. If none appear, search YouTube for Medicalgorithmics →

View all on YouTube

Press & Coverage

Investing.com
US Nasdaq-listed medtech eyes 100% of Poland's Medicalgorithmics in share-based deal
Medicalgorithmics announced on October 19, 2026, that it signed a letter of intent with a US healthcare company listed on Nasdaq, which is looking to acquire 100% of Medicalgorithmics in a share-based deal. The agreement also includes a provision for Medicalgorithmics to secure at least 10 million euros in non-debt equity financing.
2026-10
Medicalgorithmics
Medicalgorithmics Reports a 52 Percent Increase in Revenue in the Third Quarter of This Year and Higher EBITDA
Medicalgorithmics reported estimated consolidated sales revenue of PLN 10.9 million for Q3 2026, a 52% increase, along with higher EBITDA. The company is accelerating R&D projects like VCAST, AI Vesper, and Gimlet with new financing and expanding its presence in the US and European markets.
2026-10
Medicalgorithmics
Medicalgorithmics summarises Q2 2026. 56% revenue growth, positive EBITDA and PLN 3.4 millionin operating cash flow
Medicalgorithmics announced strong Q2 2026 results with consolidated revenue of PLN 10.9 million, a 56% year-on-year increase, and positive EBITDA of PLN 1.4 million. The company also reported PLN 3.4 million in operating cash flow, marking its third consecutive quarter of positive operating cash flow.
2026-09
Medicalgorithmics
Medicalgorithmics to raise up to PLN 10 million to fund R&D projects
Medicalgorithmics is securing up to PLN 10 million in financing from Biofund Capital Management to accelerate the development of its key R&D projects: VCAST, AI Vesper, and Gimlet. These projects focus on non-invasive coronary artery disease diagnosis, autonomous ECG analysis, and mass-scale cardiac prevention.
2026-09
Medicalgorithmics
Medicalgorithmics expands the reach of DeepRhythmAI to a rapidly growing U.S. cardiac monitoring platform
Medicalgorithmics has signed a three-year strategic agreement with a U.S. technology company operating a remote cardiac monitoring platform serving over 300 clinical sites. This partnership will integrate Medicalgorithmics' DeepRhythmAI (DRAI) technology for ECG analysis within the partner's ecosystem.
2026-08
Medicalgorithmics
Medicalgorithmics is entering a business talks with a global MedTech company listed on the NYSE with a multi-billion-dollar business
Medicalgorithmics has initiated talks with a global, multi-billion-dollar MedTech company listed on the NYSE for a potential collaboration. The discussions focus on the use of Medicalgorithmics' AI-based technologies in ambulatory cardiac diagnostics.
2026-06
Medicalgorithmics
FDA Approves New Version of Medicalgorithmics' DeepRhythmAI - A breakthrough in arrhythmia diagnosis
Medicalgorithmics' DeepRhythmAI (DRAI) has received FDA 510(k) clearance for its latest version of AI algorithms. This approval allows for automated ECG signal analysis using both two-lead and single-lead configurations, enhancing arrhythmia detection capabilities.
2025-06
Medicalgorithmics
Medicalgorithmics' DeepRhythmAI (DRAI), Revolutionizes Heart Diagnosis
Groundbreaking independent research published in Nature Medicine demonstrates the superior performance of Medicalgorithmics' DeepRhythmAI (DRAI) model in diagnosing cardiac arrhythmias. The study, the world's largest of its kind for AI in cardiac arrhythmia diagnosis, showed DRAI substantially outperforms traditional human technician analysis.
2025-02

Frequently Asked Questions

Medicalgorithmics offers several AI-powered products for cardiac diagnostics, including DeepRhythmAI (DRAI), which is an FDA-cleared AI algorithm suite for heart rhythm analysis that integrates with third-party software and devices. They also provide the DeepRhythm Platform (DRP), a cloud-based software leveraging AI to detect, classify, analyze, and report ECG data, and VCAST (Virtual Cardiac Stress Test), an AI-based system for non-invasive coronary artery disease assessment from CT-scan data. Additionally, they have PocketECG and Kardiobeat.ai, which are AI-driven ambulatory and wearable ECG monitors for real-time arrhythmia detection and comprehensive reporting.
Medicalgorithmics is committed to compliance and data security, maintaining an Integrated Management System in accordance with MDSAP, EN ISO 13485:2016, and ISO/IEC 27001:2022. Their DeepRhythmAI (DRAI) is FDA 510(k) cleared, CE Marked, and Health Canada licensed, and their products adhere to GDPR for data privacy. They also have a Data Protection Officer and have undergone compliance audits for cybersecurity regulations like the NIS 2 directive.
Medicalgorithmics has transitioned its business model to focus on commercializing its proprietary software and AI/ML algorithms, offering them as standalone products and integrating them with third-party devices. They license their software to clients and earn fees through various models, including those based on the volume of ECG data analyses performed. For example, new contracts are estimated to generate significant monthly recurring revenue based on analyzed ECG studies.
Medicalgorithmics offers comprehensive support, including end-to-end ECG monitoring services for clinical trials, encompassing vendor audit documentation, site training, 24/7 monitoring, and detailed diagnostic reporting. Their DeepRhythm Platform (DRP) is designed with an intuitive user interface to empower healthcare professionals with accurate and detailed reports for informed decisions. They also provide contact information for their monitoring center and compliance officer for direct assistance.
Medicalgorithmics actively seeks and forms partnerships to expand its global presence and integrate its AI solutions. They have collaborations with leading medical institutions and research centers worldwide, including the National Institute of Health and Lund University. Recent partnerships include an agreement with Accyourate, an Italian wearable healthcare company, to integrate DRAI algorithms and DRP software for remote patient monitoring, and a strategic alliance with Care Vision Health Care for distribution in Southeast Asia.
Medicalgorithmics is a publicly traded company on the Warsaw Stock Exchange and has shown recent strong financial performance. They reported a 56% year-on-year revenue growth in Q2 2026 and positive cash flow from operating activities. The company is also in talks with a potential strategic investor, a major player in cardiology, which could involve a significant equity financing round and a potential acquisition. Their strategy focuses on high-margin software and algorithm sales, particularly in the US market, to drive continued growth.

Related Companies

A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]

OpenAI is an American artificial intelligence (AI) company that conducts research and develops advanced AI models. While widely known for its generative AI models like ChatGPT and DALL-E, OpenAI has significantly expanded its focus into the healthcare sector. The company’s mission is to ensure that artificial general intelligence (AGI) benefits all of humanity, and this […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

Veeva Systems is a global leader in cloud-based software solutions specifically designed for the life sciences industry, including pharmaceutical and biotech companies. The company’s offerings are crucial for managing various aspects of drug development, pharmaceutical manufacturing, and commercial operations. Their platforms help clients navigate complex regulatory requirements, improve operational efficiency, and accelerate the delivery of […]

The University at Buffalo (UB) is a prominent public research university and a flagship institution of the State University of New York (SUNY) system. While UB itself is a broad academic institution, the provided URL (halsted.compbio.buffalo.edu) points to a specific area within UB focused on computational biology. This division is actively engaged in healthcare AI […]

Prenaital is an AI-driven healthcare company focused on revolutionizing maternal care by improving the early detection and management of high-risk pregnancies. Their AI models analyze ultrasound images to identify at-risk pregnancies, including those with abnormal fetal growth and a risk of preterm birth, with significantly higher accuracy than current clinical practices—detecting 25-50% more high-risk cases. […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.